CELC logo

Celcuity Inc. Common Stock


CELC: Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR).


Show CELC Financials

Consumer Interest
SEC Filings

Recently reported changes by institutional investors

Quarterly net insider trading by CELC's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods of preparing a primary cell sample Feb. 28, 2023
  • Patent Title: Methods of measuring signaling pathway activity for selection of therapeutic agents May. 17, 2022
  • Patent Title: Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent Jul. 27, 2021
  • Patent Title: Whole cell assays and methods Apr. 13, 2021
  • Patent Title: Whole cell assays and methods Aug. 07, 2018
  • Patent Title: Whole cell assays and methods Aug. 02, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of CELC in WallStreetBets Daily Discussion


Recent insights relating to CELC

CNBC Recommendations

Recent picks made for CELC stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CELC

Corporate Flights

Flights by private jets registered to CELC